By Anthony O. Goriainoff

AstraZeneca said Thursday that its and MSD's Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

The Anglo-Swedish pharma giant said Lynparza, in combination with abiraterone and prednisone, reduced the risk of disease progression or death by 76% versus abiraterone alone.

The company said the approval was based on a subgroup analysis of the phase 3 PROpel trial.

This Lynparza combination is approved in the EU and several other countries for the treatment of adult patients with mCRPC based on the PROpel trial, it said.

AstraZeneca said that following this approval in the U.S. it will receive a regulatory milestone payment from MSD, anticipated to be booked as collaboration revenue by the company and confirmed in the second quarter 2023 results.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

June 01, 2023 02:34 ET (06:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2023 a Ott 2023 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2022 a Ott 2023 Clicca qui per i Grafici di Astrazeneca